Skip to main content

Advertisement

SpringerLink
Log in

Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses

  • Published:
Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology

Abstract

Background: Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn’s disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoriasis. Objective: The object of our study was to evaluate the efficacy and safety of infliximab for inflammatory or autoimmune cutaneous disorders. Methods: A retrospective chart review was performed for patients who received infliximab at the University of Miami, Cedars Medical Center. Results: Patients with various disease, including panniculitis, pityriasis rubra pilaris, eosinophilic fasciitis, discoid lupus erythematosus, and necrobiosis lipoidica diabeticorum, received infliximab infusion at a dose of 5 mg/kg. All patients had refractory disease or adverse effects to previous therapy, which included cyclosporine, systemic steroids, azathioprin, clofazimine, mycophenolate mofetil, acitretin, UVB, and thalidomide. Six out of the seven patients improved after treatment. Conclusions: Infliximab was well tolerated in most patients and the majority benefited from the use of infliximab.

Antécédents:

L’infliximab est un anticorps monoclonal qui inhibe l’activité des facteurs de nécrose des tumeurs (TNF) alpha. Le médicament est approuvé aux États-Unis dans le traitement de la maladie de Crohn et de la polyarthrite rhumatoïde. Récemment, une étude contrôlée a indiqué son efficacité dans le traitement du psoriasis. Objectif: Évaluer l’efficacité et l’innocuite de l’infliximab dans le traitement des troubles cutanés inflammatoires ou auto-immuns. Méthodes: Un examen rétrospectf a été effectué des dossiers de patients ayant reçu l’infliximab au University of Miami, Cedars Medical Center. Résultats: Des patients souffrant de maladies diverses, telles que la panniculite, le pityriasis rubra pilaire, le syndrome de Schulman, le lupus érythémateux discoïde et la nécrose lipoïdique des diabétiques, ont reçu une dose de 5 mg/kg d’ifliximab par infusion. Tous les patients avaient eu des effets indésirables ou des maladies réfractaires aux traitements antérieurs, tels que la cyclosporine, les stéroïdes systémiques, l’azathioprin, la clofazimine, le mycophénolate mofetil, l’acitretin, les UVB et la thalidomide. Six patients sur sept se sent améliorés aprés le traitement. Conclusion: L’infliximab a été bien toléré par la plupart des patients et la majorité en a bénéficié.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • J Braun J Xiang J Brandt et al. (2000) ArticleTitleTreatment of spondyloarthropathies with antibodies against tumor necrosis factor alpha: first clinical and laboratory experiences. Ann Rheum Dis 59 IssueIDSuppl I i85–i89 Occurrence Handle1:CAS:528:DC%2BD3cXos1ylsrc%3D Occurrence Handle11053096

    CAS  PubMed  Google Scholar 

  • F Van den Bosch E Kruithof M De Vos et al. (2000) ArticleTitleCrohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356 IssueID9244 1821–1822 Occurrence Handle10.1016/S0140-6736(00)03239-6 Occurrence Handle1:CAS:528:DC%2BD3MXoslOh Occurrence Handle11117919

    Article  CAS  PubMed  Google Scholar 

  • EM Schwartz RJ Looney RJ O’Keefe (2000) ArticleTitleAnti-TNF alpha therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res 2 IssueID3 165–168 Occurrence Handle10.1186/ar81 Occurrence Handle11094423

    Article  PubMed  Google Scholar 

  • G Kobbe P Schneider U Rohr et al. (2001) ArticleTitleTreatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNFalpha antibody. Bone Marrow Transplant 28 IssueID1 47–49 Occurrence Handle10.1038/sj.bmt.1703094 Occurrence Handle1:STN:280:DC%2BD3MvltFajtA%3D%3D Occurrence Handle11498743

    Article  CAS  PubMed  Google Scholar 

  • DR Couriel K Hicks S Giralt et al. (2000) ArticleTitleRole of tumor necrosis alpha inhibition with infliximab in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 12 IssueID6 582–587 Occurrence Handle10.1097/00001622-200011000-00011 Occurrence Handle1:CAS:528:DC%2BD3cXos1ygtLo%3D Occurrence Handle11085458

    Article  CAS  PubMed  Google Scholar 

  • U Chaudhari P Romano LD Mulcahy et al. (2001) ArticleTitleEfficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357 1842–1847 Occurrence Handle10.1016/S0140-6736(00)04954-0 Occurrence Handle1:CAS:528:DC%2BD3MXkt1Khs74%3D Occurrence Handle11410193

    Article  CAS  PubMed  Google Scholar 

  • ALJ Ogilvie C Antoni C Dechant et al. (2001) ArticleTitleTreatment of psoriatic arthritis with antitumor necrosis factor alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144 587–589 Occurrence Handle1:CAS:528:DC%2BD3MXivVOntrk%3D Occurrence Handle11260020

    CAS  PubMed  Google Scholar 

  • AP Hughes JM Jackson JP Callen (2000) ArticleTitleClinical features and treatment of peristomal pyoderma gangrenosum. JAMA 284 1546–1548 Occurrence Handle10.1001/jama.284.12.1546 Occurrence Handle1:STN:280:DC%2BD3cvotlKqug%3D%3D Occurrence Handle11000649

    Article  CAS  PubMed  Google Scholar 

  • N Botros L Pickover KM Das (2000) ArticleTitleImage of the month: Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology 118 654–809 Occurrence Handle1:STN:280:DC%2BD3c3jt12mtA%3D%3D Occurrence Handle10777349

    CAS  PubMed  Google Scholar 

  • PH Goossens RJ Verburg FC Breedveld (2001) ArticleTitleRemission of Behcôet’s syndrome with tumor necrosis alpha blocking therapy. Ann Rheum Dis 60 IssueID6 637 Occurrence Handle10.1136/ard.60.6.637 Occurrence Handle1:STN:280:DC%2BD3M3lt1ajsw%3D%3D Occurrence Handle11350856

    Article  CAS  PubMed  Google Scholar 

  • IP Robertson P Hickling (2001) ArticleTitleTreatment of recalcitrant orogenital ulceration of Behçet’s syndrome with infliximab. Rheumatology 40 473–474 Occurrence Handle10.1093/rheumatology/40.4.473 Occurrence Handle1:STN:280:DC%2BD3M3it1Kkuw%3D%3D Occurrence Handle11312390

    Article  CAS  PubMed  Google Scholar 

  • RP Baughman EE Lower (2001) ArticleTitleInfliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 IssueID1 70 Occurrence Handle1:STN:280:DC%2BD3M3lsFGlsg%3D%3D Occurrence Handle11354550

    CAS  PubMed  Google Scholar 

  • AD Geyer GJ Anhalt HC Nossari (2000) ArticleTitleEffectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease. Arch Dermatol 136 459–460 Occurrence Handle1:STN:280:DC%2BD3c3ivFWgsg%3D%3D Occurrence Handle10768643

    CAS  PubMed  Google Scholar 

  • U Mahadevan WJ Sandborn (2001) ArticleTitleInfliximab for the treatment of orofacial Crohn’s disease. Inflamm Bowel Dis 7 IssueID1 38–42 Occurrence Handle1:STN:280:DC%2BD3M3ksFKksg%3D%3D Occurrence Handle11233659

    CAS  PubMed  Google Scholar 

  • Sullivan T, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis supprativa, submitted for publication.

  • SM Geren FA Kerdel AF Falabella et al. (2003) ArticleTitleInfliximab: A treatment option for ulcerative pyoderma gangrenosum. Wounds . IssueID. .–.

    Google Scholar 

  • J Keane S Gershon RP Wise et al. (2001) ArticleTitleTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 IssueID15 1098–l104 Occurrence Handle1:CAS:528:DC%2BD3MXnsFShsr0%3D Occurrence Handle11596589

    CAS  PubMed  Google Scholar 

  • O Nunez Martinez C Ripoll Noiseux JA Carneros Martin et al. (2001) ArticleTitleReactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 96 IssueID5 1665–1666 Occurrence Handle10.1016/S0002-9270(01)02399-1 Occurrence Handle1:STN:280:DC%2BD3M3ptF2nsg%3D%3D Occurrence Handle11374737

    Article  CAS  PubMed  Google Scholar 

  • PG Conaghan S Sommer D McGonagle et al. (1999) ArticleTitleThe relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to anti-tumor necrosis alpha immunotherapy. Arthritis Rheum 42 IssueID9 1998–2001 Occurrence Handle10.1002/1529-0131(199909)42:9<1998::AID-ANR28>3.0.CO;2-D Occurrence Handle1:STN:280:DyaK1MvktF2ktw%3D%3D Occurrence Handle10513817

    Article  CAS  PubMed  Google Scholar 

  • A Markham HM Lamb (2000;) ArticleTitleInfliximab: A review of its use in the management of rheumatoid arthritis. Drugs 59 1342–l359

    Google Scholar 

  • RN, St Maini EW Clair F Breedveld et al. (1999) ArticleTitleInfliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354 1932–1939 Occurrence Handle1:CAS:528:DC%2BD3cXit1Oquw%3D%3D Occurrence Handle10622295

    CAS  PubMed  Google Scholar 

  • InstitutionalAuthorNameAnonymous (2001) Infliximab, Mosby’s GenRx, 11th ed. C.V. Mosby, Inc. St. Louis, MO

    Google Scholar 

  • KA Papadakis SR Targan (2000) ArticleTitleTumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology 119 1148–1157 Occurrence Handle1:CAS:528:DC%2BD3cXnvV2gs7c%3D Occurrence Handle11040201

    CAS  PubMed  Google Scholar 

  • CA Dinarello (2000) ArticleTitleProinflammatory cytokines. Chest 118 IssueID2 503–509 Occurrence Handle1:CAS:528:DC%2BD3cXmtlSms7s%3D Occurrence Handle10936147

    CAS  PubMed  Google Scholar 

  • TF Schaible (2000) ArticleTitleLong term safety of infliximab. Can J Gastroenterol 14 IssueIDSuppl C 29C–52C Occurrence Handle11023558

    PubMed  Google Scholar 

  • PJ Charles RJ Smeenk J De Jong et al. (2000) ArticleTitleAssessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNFalpha: findings in label and randomized placebo controlled trials. Arthritis Rheum 43 IssueID11 2383–2390 Occurrence Handle10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4 Occurrence Handle1:CAS:528:DC%2BD3cXosFyntLc%3D Occurrence Handle11083258

    Article  CAS  PubMed  Google Scholar 

  • RA Watts (2000) ArticleTitleMusculoskeletal and systemic reactions to biological therapeutic agents. Cur Opin Rheum 12 49–52 Occurrence Handle10.1097/00002281-200001000-00008 Occurrence Handle1:STN:280:DC%2BD3c7ht1Crsg%3D%3D

    Article  CAS  Google Scholar 

  • S Bell MA Kamm (2000) ArticleTitleAntibodies to tumor necrosis factor alpha as treatment for Crohn’s disease. Lancet 355 858–860 Occurrence Handle10.1016/S0140-6736(99)00442-0 Occurrence Handle1:CAS:528:DC%2BD3cXit1Sgsro%3D Occurrence Handle10752696

    Article  CAS  PubMed  Google Scholar 

  • DL Mann (2002) ArticleTitleInflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 IssueID11 988–998

    Google Scholar 

  • DE Furst FC Breedveld GR Burmester et al. (2000) ArticleTitleUpdated consensus statement on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis 59 Suppl 1 i1–i2 Occurrence Handle1:STN:280:DC%2BD3M%2Fjt1SktA%3D%3D Occurrence Handle11053077

    CAS  PubMed  Google Scholar 

  • V Young M Ho H Vosper et al. (2002) ArticleTitleElevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology 41 IssueID8 869–875 Occurrence Handle10.1093/rheumatology/41.8.869 Occurrence Handle1:CAS:528:DC%2BD38XntFeksr8%3D Occurrence Handle12154203

    Article  CAS  PubMed  Google Scholar 

  • M Hasegawa M Fujimoto K Kikuchi et al. (1997) ArticleTitleElevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 24 IssueID4 663–665 Occurrence Handle1:STN:280:ByiB2Mnhs1M%3D Occurrence Handle9101498

    CAS  PubMed  Google Scholar 

  • A Espana E Sanchez–Yus MJ Serna et al. (1994) ArticleTitleChronic balanitis with palisading granuloma: an atypical genital localization of necrobiosis lipoidica responsive to pentoxifylline. Dermatology 188 IssueID3 222–225 Occurrence Handle1:STN:280:ByuB2czgvV0%3D Occurrence Handle8186513

    CAS  PubMed  Google Scholar 

  • KC Noz MJ Korstanje BJ Vermeer (1994) ArticleTitleUlcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol 18 IssueID1 78–79

    Google Scholar 

  • J Ordi–Ros F Cortes E Cucurull et al. (2000) ArticleTitleThalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 27 IssueID6 1429–1433 Occurrence Handle1:CAS:528:DC%2BD3cXktlKiu7s%3D Occurrence Handle10852265

    CAS  PubMed  Google Scholar 

  • VP Werth W Zhang K Dortzbach et al. (2000) ArticleTitleAssociation of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol 115 IssueID4 726–730

    Google Scholar 

  • B Fautrel V Foltz C Frances et al. (2002) ArticleTitleRegression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent. Arthritis Rheum 46 IssueID5 1408–1409 Occurrence Handle10.1002/art.10271 Occurrence Handle12115253

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida, USA

    Anna Drosou, Robert S. Kirsner, Esperanza Welsh, Tory P. Sullivan & Francisco A. Kerdel

  2. Department of Epidemiology and Public Health, University of Miami School of Medicine, Miami, Florida, USA

    Robert S. Kirsner

  3. Veterans Administration Medical Center, Miami, Florida, USA

    Robert S. Kirsner

Authors
  1. Anna Drosou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert S. Kirsner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Esperanza Welsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tory P. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francisco A. Kerdel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Kirsner.

About this article

Cite this article

Drosou, A., Kirsner, R.S., Welsh, E. et al. Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses . JCMS 7, 382–386 (2003). https://doi.org/10.1007/s10227-002-0134-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10227-002-0134-1

Keywords

Search

Navigation